SCYNEXIS, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, and reporting a net loss of $22.360 million for the nine months ended on that date.

Key Highlights

  • Net loss (nine months): $22.360 million for the nine months ended September 30, 2026, compared to $20.867 million for the same period in 2025, according to the filing.
  • Net loss (Q3 alone): $8.458 million for the three months ended September 30, 2026, versus $8.591 million in Q3 2025.
  • Cash and short-term investments: Cash and cash equivalents of $8.228 million and short-term investments of $38.937 million as of September 30, 2026.
  • March 2026 Private Placement: The company received proceeds of $40.019 million from common stock and pre-funded warrants issued in a March 2026 private placement, the filing disclosed.
  • Shares outstanding: 9,952,738 shares of common stock issued and outstanding as of September 30, 2026, up from 5,442,688 as of December 31, 2025.
  • Accumulated deficit: $407.504 million as of September 30, 2026, compared to $385.144 million as of December 31, 2025.
  • R&D expenses (nine months): $22.441 million for the nine months ended September 30, 2026, versus $17.735 million for the same period in 2025.

SCYNEXIS Financial Results and Pipeline Activity for Q3 2026

SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotech company, reported a net loss of $8.458 million for the three months ended September 30, 2026, and $22.360 million for the nine months ended September 30, 2026, according to the Form 10-Q filed November 5, 2026. Net loss per share on a basic and diluted basis was $(0.71) for the quarter and $(2.23) for the nine-month period, based on weighted average common shares outstanding of 11,842,836 and 10,037,699, respectively.

Total operating expenses for the nine months ended September 30, 2026 were $34.709 million, consisting of research and development expenses of $22.441 million and selling, general and administrative expenses of $12.268 million. The company reported no license agreement revenue for Q3 2026, compared to $334 thousand in Q3 2025; nine-month license revenue was $235 thousand in 2026 versus $1.955 million in 2025. The filing noted a warrant liabilities fair value adjustment of $(8.719) million for the nine months ended September 30, 2026, which reduced the total other income and expense line.

As of September 30, 2026, the company held $8.228 million in cash and cash equivalents and $38.937 million in short-term investments. Net cash used in operating activities was $30.452 million for the nine months ended September 30, 2026. Financing activities provided $36.904 million, driven primarily by $40.019 million in proceeds from the March 2026 private placement of common stock and pre-funded warrants. According to the filing, the company is a clinical-stage biotech focused on SCY-770, a novel AMPK activator being developed for Autosomal Dominant Polycystic Kidney Disease, which has received Orphan Drug Designation from the FDA. The company's antifungal asset BREXAFEMME (ibrexafungerp tablets) was licensed to GlaxoSmithKline Intellectual Property (No. 3) Limited in May 2023, the filing noted.

What Was Disclosed

SCYNEXIS filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a nine-month net loss of $22.360 million, an accumulated deficit of $407.504 million, and $47.165 million in combined cash and short-term investments as of September 30, 2026.